ArticleAmerican journal of cancer research2024
Nomogram-based prognostic model construction for progression to castration-resistant prostate cancer in patients with high tumor burden and osseous metastatic prostate cancer.
Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to construct a Nomogram model to predict the risk of developing castration-resistant prostate cancer (CRPC) in patients with high tumor burden (HTB) and osseous metastatic prostate cancer (PCa), and to identify key prognostic factors. A retrospective analysis was conducted on patients with HTB and osseous metastatic PCa treated at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology and the Second Affiliated Hospital of Guangzhou Medical University from January 2018 to February 2022. Patients' baseline data and laboratory indexes were collected. Cox regression analysis identified neural invasion (NI; P<0.001, HR: 2.371, 95% CI: 1.569-3.582), Gleason score (P=0.002, HR: 1.787, 95% CI: 1.241-2.573), initial PSA (P=0.004, HR: 1.677, 95% CI: 1.174-2.396), and lactate dehydrogenase (LDH; P<0.001, HR: 2.729, 95% CI: 1.855-4.014) as significant prognostic factors for progression to CRPC. The constructed Nomogram model exhibited high accuracy in predicting one- and two-year progression to CRPC, with external validation confirming its predictive performance. Time-dependent receiver operating characteristic (ROC) curves indicated that the areas under the curves (AUCs) of the model for one- and two-year progression to CRPC were 0.81 and 0.76, respectively. This model demonstrates high predictive performance, aiding clinical decision-making and providing personalized treatment strategies for patients with HTB and osseous metastatic PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.